Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion type Assertion NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_head.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion description "[A clinical trial with the sPLA(2) inhibitor varespladib methyl was recently terminated, while clinical trials with the Lp-PLA(2) inhibitor darapladib are being conducted in coronary heart disease patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_provenance.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion evidence source_evidence_literature NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_provenance.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion SIO_000772 22802388 NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_provenance.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion wasDerivedFrom befree-20140225 NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_provenance.
- NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_assertion wasGeneratedBy ECO_0000203 NP562479.RALBuQryyVF-3C1fmD1VFXp8eHQyKj-AE7OLeNpg1Sy-4130_provenance.